Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 13

1.

CTLA-4 blockade increases IFNgamma-producing CD4+ICOShi cells to shift the ratio of effector to regulatory T cells in cancer patients.

Liakou CI, Kamat A, Tang DN, Chen H, Sun J, Troncoso P, Logothetis C, Sharma P.

Proc Natl Acad Sci U S A. 2008 Sep 30;105(39):14987-92. doi: 10.1073/pnas.0806075105. Epub 2008 Sep 25.

PMID:
18818309
[PubMed - indexed for MEDLINE]
Free PMC Article
2.

Immune checkpoint proteins: a new therapeutic paradigm for cancer--preclinical background: CTLA-4 and PD-1 blockade.

Weber J.

Semin Oncol. 2010 Oct;37(5):430-9. doi: 10.1053/j.seminoncol.2010.09.005. Review.

PMID:
21074057
[PubMed - indexed for MEDLINE]
3.

The mechanism of anti-CTLA-4 activity and the negative regulation of T-cell activation.

Wolchok JD, Saenger Y.

Oncologist. 2008;13 Suppl 4:2-9. doi: 10.1634/theoncologist.13-S4-2. Review.

PMID:
19001145
[PubMed - indexed for MEDLINE]
Free Article
4.

Overcoming immunological tolerance to melanoma: Targeting CTLA-4.

Hodi FS.

Asia Pac J Clin Oncol. 2010 Mar;6 Suppl 1:S16-23. doi: 10.1111/j.1743-7563.2010.01271.x. Review.

PMID:
20482528
[PubMed - indexed for MEDLINE]
5.

[Active immunotherapy of urologic malignancies and tumor-mediated immunosuppression].

K├╝bler H, Gschwend JE.

Urologe A. 2008 Sep;47(9):1122-7. doi: 10.1007/s00120-008-1822-2. Review. German.

PMID:
18704362
[PubMed - indexed for MEDLINE]
6.

Review: anti-CTLA-4 antibody ipilimumab: case studies of clinical response and immune-related adverse events.

Weber J.

Oncologist. 2007 Jul;12(7):864-72. Review.

PMID:
17673617
[PubMed - indexed for MEDLINE]
Free Article
7.

The monoclonal antibody to cytotoxic T lymphocyte antigen 4, ipilimumab (MDX-010), a novel treatment strategy in cancer management.

Movva S, Verschraegen C.

Expert Opin Biol Ther. 2009 Feb;9(2):231-41. doi: 10.1517/14712590802643347 . Review.

PMID:
19236253
[PubMed - indexed for MEDLINE]
8.

Overcoming immunologic tolerance to melanoma: targeting CTLA-4 with ipilimumab (MDX-010).

Weber J.

Oncologist. 2008;13 Suppl 4:16-25. doi: 10.1634/theoncologist.13-S4-16. Review.

PMID:
19001147
[PubMed - indexed for MEDLINE]
Free Article
9.

Ipilimumab: controversies in its development, utility and autoimmune adverse events.

Weber J.

Cancer Immunol Immunother. 2009 May;58(5):823-30. doi: 10.1007/s00262-008-0653-8. Epub 2009 Feb 6. Review.

PMID:
19198837
[PubMed - indexed for MEDLINE]
10.

CTLA-4: negative regulator of the immune response and a target for cancer therapy.

Keilholz U.

J Immunother. 2008 Jun;31(5):431-9. doi: 10.1097/CJI.0b013e318174a4fe. Review.

PMID:
18463542
[PubMed - indexed for MEDLINE]
11.

Protective autoimmunity in cancer (review).

Toubi E, Shoenfeld Y.

Oncol Rep. 2007 Jan;17(1):245-51. Review.

PMID:
17143505
[PubMed - indexed for MEDLINE]
12.

Update on anti-CTLA-4 antibodies in clinical trials.

Langer LF, Clay TM, Morse MA.

Expert Opin Biol Ther. 2007 Aug;7(8):1245-56. Review.

PMID:
17696822
[PubMed - indexed for MEDLINE]
13.

Regulation and modulation of eosinophil effector functions.

Elsner J, Kapp A.

Allergy. 1999 Jan;54(1):15-26. Review. No abstract available.

PMID:
10195355
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk